Full-Time

Assistant Manager

Data Stewardship/Manager, Data Stewardship

Confirmed live in the last 24 hours

Deadline 6/20/25
AstraZeneca

AstraZeneca

10,001+ employees

Develops and commercializes prescription medicines

No salary listed

Mid

Chennai, Tamil Nadu, India

Minimum of three days per week in the office.

Category
Data Management
Data & Analytics
Required Skills
ServiceNow
SQL
JIRA
Data Analysis
Requirements
  • Strong analytical and problem-solving skills
  • People management experience
  • Strong knowledge on databases and database concepts, SQL, analytical tools
  • Familiarity with MS Office Tools – Word, Excel, PowerPoint
  • Document processes and adhere to standard operating procedures and processes
  • Basic project management skills and be detail oriented
  • Capable of managing multiple projects/requests simultaneously
  • Work in teams, Collaborate and ensure Compliance
  • Basic to limited exposure to issue/ticket management and/or tracking tools (ex: JIRA, ServiceNow)
Responsibilities
  • Manually update attributes of managed records to enhance core data
  • Get in touch with users for verification and updating provider affiliation information via Data Change Requests
  • Manage customer data change requests, ensuring timeliness and adherence to standard operating procedures
  • Apply business and compliance rules
  • Perform ad-hoc data analysis and extracts
  • Ensure new data elements are accurately applied without duplication
  • Audit the data quality of peers
  • Coordinate tasks with IT teams
  • Maintain alignment between CRM and MDM systems
  • Process GDPR-related requests
  • Validate client information
  • Implement process transitions and stabilization
  • Develop data quality processes
  • Automate recurring tasks
Desired Qualifications
  • Exposure to MDM tools and systems – Reltio, Veeva
  • Good experience in Process transitions, Building teams & Process Maturity model
  • Familiarity with tools like PowerBI, Snowflake, Python
  • Industry Data knowledge – OneKey, Veeva Open Data, Definitive Health Care data, Payer Data etc.

AstraZeneca develops and sells prescription medicines, focusing on three main areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Their products are created through extensive research and development, which includes clinical trials and regulatory approvals. Unlike many competitors, AstraZeneca emphasizes collaboration through its Open Innovation program and the A.Catalyst Network, which connects health innovation hubs worldwide. The company's goal is to advance healthcare by providing effective treatments for serious diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Cambridge, United Kingdom

Founded

1913

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's partnership with Danaher enhances precision medicine diagnostics development.
  • The new Rockville cell therapy facility boosts AstraZeneca's manufacturing capabilities.
  • AstraZeneca's collaboration with CSPC expands its reach in the Chinese market.

What critics are saying

  • Increased competition in oncology could impact AstraZeneca's market share.
  • Biosimilars in cardiovascular and respiratory segments may pressure AstraZeneca's pricing.
  • Regulatory changes in the EU and China could delay AstraZeneca's clinical trials.

What makes AstraZeneca unique

  • AstraZeneca's A.Catalyst Network fosters global collaboration and innovation in healthcare.
  • The company invests heavily in R&D to create new drugs and therapies.
  • AstraZeneca's Open Innovation program accelerates drug discovery through shared resources.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Paid Holidays

Flexible Work Hours

Company News

Cision
Jun 13th, 2025
Astrazeneca Enters Into Collaboration With Cspc

AstraZeneca enters into collaboration with CSPC

Cision
Jun 6th, 2025
Fixed-Duration Calquence Approved In Eu For 1L Cll

Fixed-duration Calquence approved in EU for 1L CLL

Business Weekly
Jun 5th, 2025
Sortera Bio secures £7.5m pre-seed funding

Sortera Bio, a Cambridge biotech, secured a £7.5m pre-seed round led by Cambridge Innovation Capital, with AstraZeneca and BioNTech participating. The funding will enhance Sortera's Deep Screening platform, which uses AI for drug discovery. Co-founded by Dr. Ben Porebski and Dr. Philipp Holliger, Sortera aims to deliver precision biologics. The technology was developed at the MRC Laboratory of Molecular Biology with AstraZeneca's support.

Pharmashots
Jun 2nd, 2025
AstraZeneca Presents P-III (MATTERHORN) Trial Data of Imfinzi as Perioperative Therapy for G/GEJ Cancers at ASCO 2025

AstraZeneca has shared P-III (MATTERHORN) trial data assessing perioperative Imfinzi + FLOT (n=474) vs PBO + FLOT (n=474) in 948 pts with stage II-IVA G/GEJ cancers at ASCO 2025

Cision
Jun 2nd, 2025
Block Listing Interim Review

2 June 2025 BLOCK LISTING SIX MONTHLY RETURN Information provided on this form must be typed or printed electronically and provided to an ris. (Note: Italicised terms have the same meaning as given in the Listing Rules.) Date: 2 June 2025 Name of applicant: ASTRAZENECA PLC Name of scheme: ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS -RELATED SHARE OPTION PLAN;